Allergy Drugs: Market Research Report

Date: February 22, 2010
Pages: 583
Price:
US$ 3,950.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A22937DECB4EN
Leaflet:

Download PDF Leaflet

Allergy Drugs: Market Research Report
This report analyzes the US Market for Allergy Drugs in US$ Million by the following types - Prescription Antihistamines, Prescription Corticosteroids, and OTC Allergy Drugs.

Annual forecasts are provided for the period 2007 through 2015.

The report profiles 109 companies including many key and niche players such as Collegium Pharmaceutical, Inc., McNeil Consumer Healthcare, Meda Pharmaceuticals, Inc., Novartis Consumer Healthcare, Inc., Schering-Plough Corp, Sepracor, Inc., and Vicks.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. A US MARKET REPORT

1.MARKET REVIEW

Allergy – A Global Perspective
Allergy Prevalence
Allergy - A US Perspective
Allergy Prevalence
Market Overview
Market Outlook
Manufacturers Leverage Opportunity, Announce New Product Launches
Zyrtec’ Move to OTC Aisles Perks Up OTC Sales
Allergy Patients Turn to Complimentary Medicine
Leading Allergy Products

Table 1. US Allergy Drugs Market - Percentage Share Breakdown of Antihistamine Products by New Prescriptions for 2007, 2008 and 2009 (includes corresponding Graph/Chart)
Table 2. US Allergy Drugs Market - Percentage Share Breakdown of Antihistamine + Decongestant Combination Products by New Prescription for 2007, 2008 and 2009 (includes corresponding Graph/Chart)
Table 3. US Allergy Drugs Market - Percentage Share Breakdown of Allergy Nasal Spray Products by Total Prescriptions (in thousands) for 2007 and 2008 (includes corresponding Graph/Chart)
Table 4. US Allergy Drugs Market - Percentage Share Breakdown of Allergy Nasal Spray Products by Value Sales for 2007 and 2008 (includes corresponding Graph/Chart)

2.ALLERGY OVERVIEW

Allergy: Definition
Causes/ Factors
Symptoms/ Triggers
Allergic Rhinitis – A Common Allergy
Types of Allergic Rhinitis
Diagnosis of Allergic Rhinitis
Treatment of Allergy
Antihistamines
Antihistamines - List of Select Generic Formulations and Products
Risks/ Side Effects
Decongestants
Decongestants – List of Select Generic Formulations and Products
Decongestant + Antihistamine - List of Select Generic Formulations and Products
Risks/ Side Effects
Corticosteroids
Intranasal Corticosteroids – List of Select Generic Formulations and Products
Side Effects
Allergy Shots
Other Medicines
Sodium Cromoglycate
Cromolyn Sodium
Leukotriene Modifiers
Glucocorticoids
Leading Allergy Drugs
Claritin
Zyrtec
Benadryl
Pollinex® Quattro
Cortaid
Visine-A
Ocean Sinus Irrigation
Crolom Eye Drops

3.PRODUCT INTRODUCTIONS/ APPROVALS

McNeil Consumer Healthcare Launches Zyrtec for Children
Cobalis Announces Online Launch of Anti-allergy Product
Collegium Pharmaceutical Obtains FDA Approval for AllerNaze
Sanofi-aventis and UCB Win NDA Approval for Xyzal Oral Solution
Sepracor Launches Omnaris Nasal Spray for Seasonal and Perennial Allergies
Sanofi Aventis Launches Allegra Orally Disintegrating Tablets
Ranbaxy Wins FDA Approval for Generic Zyrtec
Wockhardt Introduces Generic Cetirizine Tablets
Hi-Tech Pharmacal Receives FDA Approval for Fluticasone Propionate
Boca Pharmacal Wins FDA Approval for Palgic’s Generic Product
Ranbaxy Receives FDA Approval for Cetirizine Hydrochloride Oral Solution
Perrigo and Teva Receive FDA Approval for Zyrtec-D
Sanofi-aventis Receives FDA Approval for Nasacort AQ® Nasal Spray
Sanofi-aventis and UCB Introduce Xyzal Anti-allergy Medication
Sanofi-aventis Wins FDA Approval for Allegra® Oral Suspension
Matrixx Launches Zicam Multi-Symptom Cold & Flu Relief Products
Ranbaxy Receives Approval to Market Claritin Reditabs’ Generic
Procter & Gamble Introduces Nyquil D
Leiner to Launch Naproxen Cold & Sinus Private Label Allergy Products

4.RECENT INDUSTRY ACTIVITY

Merck Announces Business Merger Plan with Schering-Plough
Hi-Tech Pharmacal to Acquire ECR Pharmaceuticals
IBT Laboratories and ViraCor Announce Merger Plan
Lupin Acquires Rights to Collegium’s Intra-nasal Steroid
Cobalis and Melodic Sign Agreement for PreHistin
Patheon Receives Contract to Commercialize Allergy Drugs
Boehringer Ingelheim Signs Agreement for Actimis Acquisition
Perrigo Acquires US Rights to Levocetirizine Tablets
Sciele Pharma Acquires Verus Pharmaceuticals’ Allergy Injection
Sanofi-Aventis and Johns Hopkins University Division Sign Agreement
Pipex Announces Effective Pharmaceuticals Acquisition
Meda to Take Over American Company, MedPointe
Private Group Proposes to Acquire Majority Interest in Inyx

5.FOCUS ON SELECT PLAYERS

Collegium Pharmaceutical, Inc.
McNeil Consumer Healthcare
Meda Pharmaceuticals, Inc.
Novartis Consumer Healthcare, Inc.
Schering-Plough Corp.
Sepracor, Inc.
Vicks

6.US MARKET PERSPECTIVE

Table 5. US Recent Past, Current & Future Analysis for Allergy Drugs by Product Segment – Prescription Antihistamines, Prescription Corticosteroids and OTC Allergy Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 6. US Historic Review for Allergy Drugs by Product Segment – Prescription Antihistamines, Prescription Corticosteroid and OTC Allergy Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 7. US 15-Year Perspective for Allergy Drugs by Product Segment – Percentage Breakdown of Annual Value Sales for Prescription Antihistamines, Prescription Corticosteroids and OTC Allergy Drugs Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

III. REST OF WORLD MARKETS

1.CANADA

Allergy – Overview
Strategic Corporate Developments

2.JAPAN

Allergy – Overview
Product Approvals

3.EUROPE

Allergy - Prevalence
United Kingdom
Allergy – Overview
Russia
Allergy – Overview
Product Launch
Strategic Corporate Developments
Select Players

4.ASIA-PACIFIC

Allergy – Overview
Australia and New Zealand
China
Market Overview
OTC Medications – A Small, But Growing Market
Market Analytics

Table 8. Chinese Recent Past, Current & Future Analysis for Allergy Drugs – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

India
Market Overview
Malaysia
Allergy – Overview

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 109 (including Divisions/Subsidiaries - 139)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle-east
Africa
Skip to top


Allergy Drugs Market Research (China) US$ 4,000.00 Mar, 2016 · 207 pages
Allergy Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 1315 pages
Ophthalmic Drugs: World Market Prospects 2013-2023 US$ 2,635.00 Mar, 2013 · 222 pages
World OTC Pharmaceutical Market 2012-2022 US$ 2,635.00 Jun, 2012 · 147 pages

Ask Your Question

Allergy Drugs: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: